Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

At Soleno, we are researching and developing medicines to treat rare genetic disorders, beginning with Prader-Willi syndrome (PWS), a life-threatening neurobehavioral, metabolic and endocrine disorder characterized by hyperphagia (insatiable hunger), neurocognitive and behavioral difficulties. Our lead candidate, DCCR, is a Phase 3, once-daily oral tablet under investigation as a potential treatment for PWS. Our priority is to bring the first approved treatment to patients to manage the most burdensome aspects of this devastating disorder.

We’re wishing a safe and fun holiday season for all in our community! Holidays can be a special time of togetherness for family and friends, but they can also be stressful – particularly for families living with #PraderWilliSyndrome. Check out these tips for the winter holiday season from Prader-Willi Syndrome Association | USA. https://bit.ly/3RvhxRF 

We appreciate the advocacy efforts of Congressman Paul Tonko (D-NY) recognizing the need for greater consistency in regulatory reviews of much-needed investigational treatments for #RareDiseases, 95% of which currently have no FDA-approved treatments. We also appreciate that he specifically shed a light on the unmet needs in the #PraderWilliSyndrome community in his recent letter to the FDA. Read it here: https://lnkd.in/gcmmeGug

To better understand the impact of hyperphagia (genetically implicated insatiable appetite) on people with #PraderWilliSyndrome, watch “My Deadly Appetite,” a Discovery Channel documentary in three 15-minute segments. Part 1: https://lnkd.in/dtviyEFJ 

#PraderWilliSyndrome is the most common genetic cause of hyperphagia, a life-threatening extreme drive to seek and consume food. It affects approximately 350,000-400,000 people worldwide of all genders and ethnic backgrounds. Learn more: https://bit.ly/49W1LGN

Check out this inspiring video from Prader-Willi Syndrome Association | USA in which Erin Carter shares about her daughter’s journey with #PraderWilliSyndrome and her own journey to becoming an advocate on behalf of her daughter and the entire PWS community. https://bit.ly/412S1qa 

NASDAQ:SLNO

GARDENA

Last Close

46.95

26/07 20:00

Market Cap

1.57B

Beta: 0.19

Volume Today

201.37K

Avg: 45.39K

PE Ratio

−18.05

PFCF: −63.63

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics